License and Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Year Ended December 31,
Partner	Agreement	2013		2012		2011
AstraZeneca AB	Naloxegol (NKTR-118) and naloxegol fixed-dose combination program (NKTR-119)	$	25,016	$	59	$	2,496
Roche	PEGASYS® and MIRCERA®		18,382		7,146		5,131
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)		15,293		2,971		2,992
Affymax, Inc.	OMONTYS®		7,149		2,829		3,838
Amgen, Inc.	Neulasta®		5,035		5,000		5,000
Baxter Healthcare	BAX 855 (Hemophilia)		1,702		6,238		5,646
Other			8,295		5,884		11,186
License, collaboration and other revenue		$	80,872	$	30,127	$	36,289